INNOVIVA, INC. Income (Loss) from Continuing Operations, Per Diluted Share
INNOVIVA, INC. (INVA) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.53 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2017-02-28
- INNOVIVA, INC. income (loss) from continuing operations, per diluted share for fiscal 2016 was $0.53.
- INNOVIVA, INC. income (loss) from continuing operations, per diluted share for fiscal 2015 was -$0.16.
- INNOVIVA, INC. income (loss) from continuing operations, per diluted share for fiscal 2014 was -$0.66.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|
| 2016-12-31 | $0.53 10-K · filed 2017-02-28 |
| 2015-12-31 | -$0.16 10-K · filed 2017-02-28 |
| 2014-12-31 | -$0.66 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |